Destiny Pharma: Who is the new CEO?
This week announced the appointment of a new CEO, Chris Tovey, and he comes with a very impressive track record.
In this video I look at Chris’s career & why he would be attracted to Destiny Pharma.
Destiny Pharma is a clinical phase biotechnology company dedicated to infection prevention. The company has two late stage clinical programmes and an earlier preclinical pipeline. The strategy is to build strong clinical data packages and then seek partners for the final clinical studies and commercialisation.
Three seperate brokers have a target, the average of which is 860% above the current share price and this is less than half the potential if you take into account their other late stage asset and earlier pipeline.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.